DBV Technologies (DBVT) Other Non-Current Assets (2015 - 2026)
DBV Technologies (DBVT) posted Other Non-Current Assets of $5.8 million for Q2 2026, up 7.41% sequentially from $5.4 million in Q1 2026, and up 8.76% YoY from $5.3 million in Q2 2025.
DBV Technologies (DBVT) Other Non-Current Assets (2015 - 2026) Analysis & Trends
DBV Technologies has reported Other Non-Current Assets for 12 years, with the latest figure at $5.8 million in Q2 2026.
- Quarterly Other Non-Current Assets rose 8.76% year-over-year to $5.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.8 million (up 8.76% YoY) and the FY2025 annual result came in at $5.8 million, up 31.13% from the prior year.
- Other Non-Current Assets improved to $5.8 million in Q2 2026 per DBVT's latest filing, from $5.4 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $6.8 million in Q1 2024 and troughed at $4.4 million in Q4 2024.
- A 5-year average of $5.7 million and a median of $5.8 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets slumped 84.03% in 2022, then surged 31.13% in 2025.
- Over 5 years, Other Non-Current Assets stood at $5.8 million in 2022, then climbed by 5.49% to $6.1 million in 2023, then retreated by 28.01% to $4.4 million in 2024, then soared by 31.13% to $5.8 million in 2025, then changed by 0.0% to $5.8 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $5.8 million, $5.4 million, and $5.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 5.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.80 Mn |
| Mar 31, 2026 | 5.40 Mn |
| Dec 31, 2025 | 5.80 Mn |
| Sep 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 5.33 Mn |
| Mar 31, 2025 | 4.96 Mn |
| Dec 31, 2024 | 4.42 Mn |
| Sep 30, 2024 | 5.28 Mn |
| Jun 30, 2024 | 5.35 Mn |
| Mar 31, 2024 | 6.82 Mn |
| Dec 31, 2023 | 6.14 Mn |
| Sep 30, 2023 | 5.97 Mn |
| Jun 30, 2023 | 5.94 Mn |
| Mar 31, 2023 | 5.77 Mn |
| Dec 31, 2022 | 5.82 Mn |
| Sep 30, 2022 | 5.37 Mn |
| Jun 30, 2022 | 6.19 Mn |
| Mar 31, 2022 | 6.58 Mn |
| Dec 31, 2021 | 6.83 Mn |
| Sep 30, 2021 | 33.61 Mn |